{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:10Z","timestamp":1787008630166,"version":"build-2736575974"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2015,9,15]]},"DOI":"10.1093\/cid\/civ522","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T09:19:03Z","timestamp":1440667143000},"page":"S38-S47","source":"Crossref","is-referenced-by-count":34,"title":["Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions"],"prefix":"10.1093","volume":"61","author":[{"given":"Eric","family":"Wenzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Rodvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,27]]},"reference":[{"key":"2015082705480082000_61.suppl_2.S38.1","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Available at: http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf . Accessed 26 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit614"},{"key":"2015082705480082000_61.suppl_2.S38.3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199701)17:1<69::AID-MED3>3.0.CO;2-R"},{"key":"2015082705480082000_61.suppl_2.S38.4","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.57.326"},{"key":"2015082705480082000_61.suppl_2.S38.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.08.067"},{"key":"2015082705480082000_61.suppl_2.S38.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3602-3604.2003"},{"key":"2015082705480082000_61.suppl_2.S38.7","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480082000_61.suppl_2.S38.8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"2015082705480082000_61.suppl_2.S38.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00933-10"},{"key":"2015082705480082000_61.suppl_2.S38.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.02.007"},{"key":"2015082705480082000_61.suppl_2.S38.11","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.979789"},{"key":"2015082705480082000_61.suppl_2.S38.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3043-3050.2004"},{"key":"2015082705480082000_61.suppl_2.S38.13","unstructured":"Lodise TP , Patel N , Hegde S , Barriere S , Shaw J , Drusano G . Mouse thigh MRSA infection model data and mathematical modelling to determine telavancin dosing for complicated skin and skin structure infection trials [abstract 469]. In: 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, 2010."},{"key":"2015082705480082000_61.suppl_2.S38.14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl222"},{"key":"2015082705480082000_61.suppl_2.S38.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3163-3165.2005"},{"key":"2015082705480082000_61.suppl_2.S38.16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00922-12"},{"key":"2015082705480082000_61.suppl_2.S38.17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm417"},{"key":"2015082705480082000_61.suppl_2.S38.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00062-10"},{"key":"2015082705480082000_61.suppl_2.S38.19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.770-773.2006"},{"key":"2015082705480082000_61.suppl_2.S38.20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn490"},{"key":"2015082705480082000_61.suppl_2.S38.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01101-08"},{"key":"2015082705480082000_61.suppl_2.S38.22","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn273"},{"key":"2015082705480082000_61.suppl_2.S38.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01750-09"},{"key":"2015082705480082000_61.suppl_2.S38.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"2015082705480082000_61.suppl_2.S38.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05915-11"},{"key":"2015082705480082000_61.suppl_2.S38.26","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks103"},{"key":"2015082705480082000_61.suppl_2.S38.27","unstructured":"Duchin K , Shaw J , Seroogy J et al . Effect of hemodialysis on single dose pharmacokinetics of telavancin [abstract P 897]. In: Program and abstracts of the 15th European Congress of Clinical Microbiology and Infectious Disease (Copenhagen, Denmark), 2005."},{"key":"2015082705480082000_61.suppl_2.S38.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.09.002"},{"key":"2015082705480082000_61.suppl_2.S38.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.788-790.2006"},{"key":"2015082705480082000_61.suppl_2.S38.30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-07"},{"key":"2015082705480082000_61.suppl_2.S38.31","unstructured":"Vibativ (telavancin) Prescribing Information. Theravance Biopharma Antibiotics, Inc. December 2014. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022110s011lbl.pdf . Accessed 9 March 2015."},{"key":"2015082705480082000_61.suppl_2.S38.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00383-11"},{"key":"2015082705480082000_61.suppl_2.S38.33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/039139880903201006","article-title":"Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study","volume":"32","author":"Patel","year":"2009","journal-title":"Int J Artif Organs"},{"key":"2015082705480082000_61.suppl_2.S38.34","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22109"},{"key":"2015082705480082000_61.suppl_2.S38.35","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl424"},{"key":"2015082705480082000_61.suppl_2.S38.36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-07"},{"key":"2015082705480082000_61.suppl_2.S38.37","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ535","article-title":"The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia","author":"Sandrock","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480082000_61.suppl_2.S38.38","unstructured":"Food and Drug Administration Anti-Infective Drugs Advisory Committee Briefing Document. Telavancin for the Treatment of Complicated Skin and Skin Structure Infections. 19 November 2008. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4394b2-01-FDA.pdf . Accessed 30 December 2014."},{"key":"2015082705480082000_61.suppl_2.S38.39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02330-13"},{"key":"2015082705480082000_61.suppl_2.S38.40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"2015082705480082000_61.suppl_2.S38.41","unstructured":"Food and Drug Administration Anti-Infective Drugs Advisory Committee Meeting. Telavancin for the Treatment of Nosocomial Pneumonia. 29 November 2012. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM329482.pdf . Accessed 3 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.42","unstructured":"Johnson & Johnson Pharmaceutical Research & Development. Doripenem for injection for the treatment of nosocomial pneumonia. Meeting of Anti-Infective Drugs Advisory Committee: July 16, 2008. Advisory Committee Briefing Book. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4364b1-02-Johnson.pdf . Accessed 12 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.43","doi-asserted-by":"publisher","DOI":"10.1086\/653065"},{"key":"2015082705480082000_61.suppl_2.S38.44","doi-asserted-by":"publisher","DOI":"10.1086\/653059"},{"key":"2015082705480082000_61.suppl_2.S38.45","doi-asserted-by":"publisher","DOI":"10.1086\/653038"},{"key":"2015082705480082000_61.suppl_2.S38.46","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"2015082705480082000_61.suppl_2.S38.47","unstructured":"Center For Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for Industry. Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment. Draft guidance. May 2014. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM234907.pdf . Accessed 9 March 2015."},{"key":"2015082705480082000_61.suppl_2.S38.48","unstructured":"European Medicines Agency. Press release. Astellas withdraws its marketing authorisation application for Vibativ (telavancin). 24 October 2008. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500007387.pdf . Accessed 12 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.49","unstructured":"Press release. Clinigen reports pan European lifting of MA suspension for Vibativ. 18 March 2014. Available at: http:\/\/www.clinigengroup.com\/media\/news\/clinigen-reports-pan-european-lifting-of-ma-suspension-vibativr . Accessed 12 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.50","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu971"},{"key":"2015082705480082000_61.suppl_2.S38.51","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr234"},{"key":"2015082705480082000_61.suppl_2.S38.52","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00857-10"},{"key":"2015082705480082000_61.suppl_2.S38.53","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq113"},{"key":"2015082705480082000_61.suppl_2.S38.54","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1111\/tid.12123","article-title":"Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia","volume":"15","author":"Swartz","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"2015082705480082000_61.suppl_2.S38.55","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2014.995696"},{"key":"2015082705480082000_61.suppl_2.S38.56","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-289"},{"key":"2015082705480082000_61.suppl_2.S38.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.06.003"},{"key":"2015082705480082000_61.suppl_2.S38.58","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr329"},{"key":"2015082705480082000_61.suppl_2.S38.59","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q331"},{"key":"2015082705480082000_61.suppl_2.S38.60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02127-12"},{"key":"2015082705480082000_61.suppl_2.S38.61","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01544-08"},{"key":"2015082705480082000_61.suppl_2.S38.62","unstructured":"Theravance Biopharma Antibiotics, Inc. Telavancin Observational Use Registry (TOUR). Clinicaltrials.gov identifier NCT02288234. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02288234 . Accessed 15 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.63","unstructured":"Theravance Biopharma Antibiotics, Inc. Press release. Theravance Biopharma provides Vibativ (telavancin) product update: plans for new clinical studies, expanded commercial program and new study analyses further supporting drug's in vitro potency in resolving difficult to treat infections. 9 September 2014. Available at: http:\/\/investor.theravance.com\/releasedetail.cfm?releaseid=869836 . Accessed 13 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.64","unstructured":"Theravance Biopharma Antibiotics, Inc. A phase 3 telavancin Staphylococcus aureus bacteremia trial. Clinicaltrials.gov identifier NCT02208063. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02208063 . Accessed 15 January 2015."},{"key":"2015082705480082000_61.suppl_2.S38.65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"2015082705480082000_61.suppl_2.S38.66","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01710-08"},{"key":"2015082705480082000_61.suppl_2.S38.67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03172-14"},{"key":"2015082705480082000_61.suppl_2.S38.68","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01210-14"},{"key":"2015082705480082000_61.suppl_2.S38.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.006"},{"key":"2015082705480082000_61.suppl_2.S38.70","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr518"},{"key":"2015082705480082000_61.suppl_2.S38.71","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-013-1004-y"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_2\/S38\/1113391\/civ522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:35:32Z","timestamp":1718033732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,27]]},"references-count":71,"journal-issue":{"issue":"suppl 2","published-online":{"date-parts":[[2015,8,27]]},"published-print":{"date-parts":[[2015,9,15]]}},"alternative-id":["10.1093\/cid\/civ522"],"URL":"https:\/\/doi.org\/10.1093\/cid\/civ522","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,27]]}}}